NEM vs OCUL · P/E 14, rev $13.43B vs rev $24.3M
Newmont Goldcorp Corp (NEM) versus Ocular Therapeutix Inc (OCUL) — a side-by-side from cached financials, not a winner call.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Ocular Therapeutix Inc (OCUL) is a biotechnology company listed on US.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Latest reported OCUL revenue for 2026-06-30 was $24.3M. Net income was -$167.4M. OCUL currently screens at market cap $1.76B.
NEM currently screens at market cap $112.81B and trailing P/E 13.7. OCUL currently screens at market cap $1.76B.
Not investment advice. Open the NEM and OCUL stock pages for the full models.
Not investment advice.